Immunomodulation induced by tucaresol in HIV infection: Results of a 16 week pilot Phase I/II trial

Andrea Gori, Daria Trabattoni, Alessandra Bandera, Marina Saresella, Giulia Marchetti, Lidia Gazzola, Mara Biasin, John Rhodes, Hugh McDade, Ruggero Panebianco, Massimo Galli, Mauro Moroni, Pasquale Ferrante, Nicola Thomas, Fabio Franzetti, Dorothy Bray, Mario Clerici

Research output: Contribution to journalArticlepeer-review

Abstract

Objective: Immune reconstitution in highly active antiretroviral therapy (HAART)-treated individuals is incomplete and immunomodulatory compounds are needed to improve the outcome of HIV therapy. In a Phase I/II clinical trial performed on HIV-positive patients we analysed the safety and immunomodulating effects of tucaresol, a novel compound that has previously been described to enhance cell-mediated immune responses. Patients and methods: Sixteen weeks pulse dose escalation protocol. Four groups of HIV-positive patients were enrolled: group A (n=6): HAART, CD4+ 300-500 cells/μl, HIV RNA 10 000 copies/ml; group C (n=3): HAART-naive, CD4+ >500 cells/μl, HIV RNA

Original languageEnglish
Pages (from-to)603-614
Number of pages12
JournalAntiviral Therapy
Volume9
Issue number4
Publication statusPublished - Aug 2004

ASJC Scopus subject areas

  • Pharmacology

Fingerprint

Dive into the research topics of 'Immunomodulation induced by tucaresol in HIV infection: Results of a 16 week pilot Phase I/II trial'. Together they form a unique fingerprint.

Cite this